Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 3/20 | 0.43 |
| ▸ | MC5R | P33032 | 3/20 | 0.43 |
| ▸ | MC3R | P41968 | 3/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862071 | 1.00 | AGER (0.47) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL3370759 | 0.88 | AGER (0.55) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL77425 | 0.84 | MC4R (0.54) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL738277 | 0.84 | MC4R (0.54) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL736913 | 0.82 | AGER (0.50) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL736914 | 0.82 | AGER (0.50) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL2400009 | 0.81 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL13275447 | 0.81 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL2400012 | 0.81 | OPRM1 (0.51) | AGERMTNR1ACHRM2CHRM3OPRM1 | |
| SCHEMBL481562 | 0.80 | YTHDC1 (0.49) | MEN1KMT2AMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7273880-B2 | Selective NPY (Y5) antagonists | H. LUNBECK A/S (DK) | 2007-09-25 | — | — | US | disclosed |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-06-23 | — | — | US | disclosed |
| EP-1194421-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1194421-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6225330-B1 | Selective NPY (Y5) antagonists (tricyclics) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| WO-2001002379-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137240-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | AGER 1009/4885MTNR1A 298/4885CHRM2 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.